News and features
Read the latest news and features about our world-leading research, discoveries, fundraising and philanthropy. If you want to keep updated on our news, you can follow us on social media or sign up for our Search newsletter.
If you’re a journalist and want to find out more, you can contact our media relations team.
Imaging tumour stiffness could help enhance treatment for breast and pancreatic cancer
Using a non-invasive imaging technique that measures the stiffness of tissues gives crucial new information about cancer architecture and could aid the delivery of treatment to the most challenging tumours, new research shows.
New Athena SWAN Silver Award recognises ICR’s work on diversity and access to opportunities
The ICR is celebrating the work of all our staff and students in creating an open, diverse and fully inclusive environment, with the award of an Athena SWAN Charter Silver Award for 2019-23.
New evolution-busting drug overcomes resistance in aggressive breast cancers
A new type of drug that blocks one of cancer’s key evolutionary escape routes from chemotherapy could be used to treat aggressive breast cancers, a new study has shown.
ICR forms collaboration with AI drug discovery company to develop new possible treatments in rare childhood cancer DIPG
Scientists at The Institute of Cancer Research are working with Healx, a biotech company specialising in artificial intelligence (AI) to discover new possible ways of treating diffuse intrinsic pontine glioma (DIPG), an essentially untreatable brain cancer in children.
Gut bacteria ‘fingerprint’ predicts radiotherapy side effects
Taking a ‘fingerprint’ of the mix of bacteria in the gut can indicate how susceptible individual cancer patients are to gut damage as a result of radiotherapy for prostate and gynaecological cancers, a new study shows.
ESMO 2019: Breast and ovarian cancer drug outperforms targeted hormone therapy in some men with advanced prostate cancer
A drug used for breast and ovarian cancer is more effective than modern targeted hormone treatments at slowing progression and improving survival in some men with advanced prostate cancer, phase III clinical trial findings reveal.
ESMO 2019: Modern chemotherapy drug better than second targeted hormone therapy against resistant prostate cancer
A modern chemotherapy drug is more effective for men with advanced prostate cancer than a second targeted hormone therapy in patients who have stopped responding to treatment, a major clinical trial shows.
Scientists develop new way to study spread of devastating childhood cancer
New research has helped create a mouse model to help study a devastating childhood cancer and understand how it spreads.
ESMO 2019: Combination immunotherapy drugs offer new hope for melanoma patients
A combination of two immunotherapy drugs, ipilimumab and nivolumab, stops or reverses the progression of advanced melanoma – with long term survival rates hitting an all-time high – according to a study presented at the ESMO Congress.
ESMO 2019: Largest ever trial in postoperative prostate cancer patients confirms that men can be spared radiotherapy after surgery
Men with prostate cancer can be spared radiotherapy after surgery, according to late breaking results from a study presented at the ESMO Congress in Barcelona.
Study signals new era of precision medicine for children with cancer
A new study has shown the power of genetic testing to pick out the best drugs for children with cancer to extend and improve their lives – signalling a new era of precision medicine for young patients.
Combination therapies could help treat fatal lung cancers
Combining a new class of drug with two other compounds can significantly shrink lung tumours in mice and human cancer cells, finds a new study led by the Francis Crick Institute and The Institute of Cancer Research, London.
